Article Versions Notes

Mukherjee N, Amato CM, Skees J, Todd KJ, Lambert KA, Robinson WA, Van Gulick R, Weight RM, Dart CR, Tobin RP, et al. Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma. Cancers. 2020; 12(8):2182. https://doi.org/10.3390/cancers12082182

Mukherjee, Nabanita, Carol M. Amato, Jenette Skees, Kaleb J. Todd, Karoline A. Lambert, William A. Robinson, Robert Van Gulick, Ryan M. Weight, Chiara R. Dart, Richard P. Tobin, and et al. 2020. "Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma" Cancers 12, no. 8: 2182. https://doi.org/10.3390/cancers12082182

Mukherjee, N., Amato, C. M., Skees, J., Todd, K. J., Lambert, K. A., Robinson, W. A., Van Gulick, R., Weight, R. M., Dart, C. R., Tobin, R. P., McCarter, M. D., Fujita, M., Norris, D. A., & Shellman, Y. G. (2020). Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma. Cancers, 12(8), 2182. https://doi.org/10.3390/cancers12082182